Bradanicline

Bradanicline

File:Bradanicline structure.svg
Clinical data
Other names	TC-5619
Identifiers
IUPAC name N-[(2S,3R)-2-(Pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2- carboxamide
CAS Number	639489-84-2
PubChem CID	16727410
IUPHAR/BPS	3969
ChemSpider	20559152
UNII	UM3821998K
KEGG	D10613 checkY
ChEMBL	ChEMBL1258006
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C22H23N3O2
Molar mass	361.445 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CN2CCC1[C@@H]([C@@H]2CC3=CN=CC=C3)NC(=O)C4=CC5=CC=CC=C5O4
InChI InChI=1S/C22H23N3O2/c26-22(20-13-17-5-1-2-6-19(17)27-20)24-21-16-7-10-25(11-8-16)18(21)12-15-4-3-9-23-14-15/h1-6,9,13-14,16,18,21H,7-8,10-12H2,(H,24,26)/t18-,21-/m0/s1 Key:OXKRFEWMSWPKKV-RXVVDRJESA-N
(verify)

Bradanicline (INN; development code TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. Phase I clinical trials were completed successfully, and it was in phase II trials.

In May 2011, AstraZeneca declined to exercise its right to license the compound. In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults. It was being studied for cognitive and memory enhancement.

Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late-2013. It was also discontinued for ADHD.